QuatCy-I2 and MHI-I2 in Photodynamic Therapy

ACS Med Chem Lett. 2022 Feb 18;13(3):470-474. doi: 10.1021/acsmedchemlett.1c00640. eCollection 2022 Mar 10.


MHI-I2 (1) and QuatCy-I2 (2) were compared in terms of properties important for early-stage photodynamic therapy preclinical candidates. Thus, experiments were performed to monitor dark cytotoxicities, light/dark cytotoxicity ratios, selectivity of localization in tumors over other organs, and clearance from the plasma.